Edwards Lifesciences Corp reported revenue of $1.74B for the period ended 2026-06-30, +13.6% year on year. Net income was $0.24B, a 13.9% net margin on a 77.5% gross margin. The largest revenue line is Transcatheter Aortic Valve Replacement at 72% of the total. Free cash flow for the period was $0.58B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $1.74B | +13.6% |
| Gross profit | $1.35B | — |
| Operating income | $0.51B | — |
| Net income | $0.24B | -27.4% |
| Gross margin | 77.5% | Net margin 13.9% |
| Revenue Q/Q | +5.6% | — |
| Segment | Revenue | Share |
|---|---|---|
| Transcatheter Aortic Valve Replacement | $1.26B | 72.3% |
| Surgical | $0.28B | 16.3% |
| Transcatheter Mitral And Tricuspid Therapies | $0.20B | 11.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $0.39B | 22.5% |
| R&D | $0.28B | 16.0% |
| SG&A | $0.56B | 32.2% |
| Tax & other | $0.27B | 15.6% |
| Item | Amount |
|---|---|
| Total assets | $13.87B |
| Total liabilities | $3.14B |
| Shareholders' equity | $10.72B |
| Equity / assets | 77.3% |
| Operating cash flow | $0.65B |
| Capital expenditure | $0.07B |
| Free cash flow | $0.58B |
| Cash conversion (OCF / net income) | 269% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
ELV ・ EME ・ EMR ・ ETR ・ EOG ・ EQT ・ EFX ・ EQIX ・ EQR ・ ERIE ・ ESS ・ EL
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies